Stakeholder Opinions: Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success
Healthcare
Introduction
Factors influencing a prescribing decision can diverge from clinical facts. In the highly competitive autoimmune area, misconceptions and physician habits can result in loss of sales. Targeted detailing of specialist... |
Commercial Insight: HIV - The battle for market share is getting fiercer
Introduction
In 2007, HIV drugs achieved sales of $9.3 billion in the 7MM, growing faster than the overall market at a CAGR of 11.3% from 2004-2007. Due to patent expirations, Datamonitor... |
Strategic Perspectives: Antidyslipidemics Current market is not conducive for growth
Introduction
The antidyslipidemic market is increasingly governed by cost concerns which appear to be more pressing than the safety and efficacy concerns. Cost-saving initiatives together with the continuing genericization are going... |
A Guide to Drug Pricing and Reimbursement
Drug pricing is one of the key levers that determine the profitability of a drug company. Premium pricing of a new drug helps cover the high cost of innovation and... |
Commercial and Pipeline Insight: Psoriasis
Established brands challenged by new therapies
In this report, Datamonitor assesses the main events which shaped the
psoriasis market in the past five years, and speculates on major events
set to impact over the next ten... |
Emerging Markets Series: The Pharmaceutical Market of Saudi Arabia
Introduction
The Saudi Arabian pharmaceutical sector is becoming increasingly attractive for multinationals to enter driven by the expansion of private healthcare and altering patient demographics; and also for domestic generics companies... |
Opthalmic Pharmaceutical Drugs
This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ million by the following Therapeutic Categories:
Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye, and Others.
The report provides... |
Stakeholder Insight: Pricing and Reimbursement in Oncology
Do payers believe oncology drugs offer good value?
Introduction
The oncology market has shown remarkable growth in recent years, driven by the advent of targeted therapy and the high level of unmet needs in the disease, and it is... |
Oncology Market Leaders
Analyses and Outlook – 2010-2025
Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in... |
Veterinary Formulary
6th Edition
The sixth edition of The Veterinary Formulary has been updated and revised by 51 expert contributors and reviewed by an advisory committee of veterinarians and pharmacologists. Features of... |
Stakeholder Insight: Supportive Care in Cancer Treatment
Some first-generation products proving difficult to dislodge
Introduction
Supportive care is used to prevent or treat the adverse effects that arise as a result of cancer treatment, particularly chemotherapy. While newer molecular targeted therapies do not exist without... |
Preparing Health Technology Submissions for Pharmaceutical Products
Meeting Formulary Submission Requirements for New Product Assessments and Disease Area & Therapeutic Class Reviews
Preparing health technology submissions for pharmaceutical products - Meeting Formulary Submission Requirements for New Product Assessments and Disease Area and Therapeutic Class Reviews, considers how manufacturers should respond to emerging... |
Medicare Prescription Drug Benefit
Profits and Pitfalls
One of the things those living in other countries find most difficult to understand about the US is that its healthcare system is no system at all. Never designed by... |
Pricing & Reimbursement in Asia-Pacific
Generic drugs (generics) are now an established part of pharmaceutical markets and healthcare policies around the world. According to IMS Health data, they already account for 63% of all prescriptions... |
Nurse Prescribers Formulary 2005-2007
For Community Practitioners
This work is designed for use by nurse prescribers (District Nurses or Health Visitors who have completed the nurse
prescribers training scheme).
It contains details of preparations which nurses may prescribe for... |
Health Economics in the Drug Life Cycle
Achieving success in drug discovery, development, reimbursement and marketing
The increasingly cost-conscious nature of formulary decisions and the willingness of reimbursers to reject a drug for listing on budget impact grounds means that drug companies must address the issue... |
